Abstract-Acetylcholine (ACh) acts through nicotinic and muscarinic ACh receptors in the ventral midbrain and striatal areas to influence dopamine (DA) transmission. This cholinergic control of DA transmission is important for processes such as attention and motivated behavior, and is manipulated by nicotine in tobacco products. Identifying and characterizing the key ACh receptors involved in cholinergic control of DA transmission could lead to small molecule therapeutics for treating disorders involving attention, addiction, Parkinson's disease, and schizophrenia.
INTRODUCTION
The brain dopamine (DA) pathway is a crucial neurotransmitter system involved in a myriad of processes, including reward/reinforcement, attention, cognition, and voluntary movement. DA neurons in the ventral tegmental area (VTA) that project to nucleus accumbens (NAc) make up the mesolimbic DA pathway, whereas DA neurons in the substantia nigra pars compacta (SNc) that project to the dorsal striatum comprise the nigrostriatal DA pathway. Disrupted DA transmission causes the cardinal features of Parkinson's disease as well as addiction to drugs of abuse, and is clearly implicated in disorders such as schizophrenia, bipolar disorder, mood disorders, and attention deficit hyperactivity disorder. Cholinergic signaling strongly regulates the DA system in animal models and human disease. For example, in Parkinson's disease, enhanced cholinergic signaling often plays a role in the pathological circuit changes that give rise to the motor features of the disease (Pisani et al., 2007) . Brain areas rich in DAproducing cell bodies and axon terminals receive dense cholinergic innervation, and numerous proteins involved in cholinergic transmission are expressed in these areas Butcher, 1981, 1986; Bolam et al., 1984) . These include acetylcholinesterase, choline acetyltransferase, muscarinic acetylcholine (ACh) receptors, and nicotinic acetylcholine receptors (nAChRs). Recently, nAChRs have emerged as crucial regulators of DA transmission (Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley and Cragg, 2008; Cachope et al., 2012; Threlfell et al., 2012) , and many groups are actively searching for novel compounds designed to specifically manipulate nAChRs in the DA system. nAChRs in the central nervous receptors comprised of multiple a and b subunits. a4b2 * (* indicates a receptor containing the indicated subunits but may contain other unknown subunits) nAChRs exhibit widespread expression in the brain (Nashmi et al., 2007; Shih et al., 2014) , along with high affinity for nicotine and ACh (Salminen et al., 2004 (Salminen et al., , 2007 Grady et al., 2010) . a4b2 * nAChRs are both necessary and/or sufficient for most aspects of nicotine addiction in mouse models, including reward, self-administration, tolerance, behavioral and cellular sensitization, and enhanced firing of VTA DA neurons (Tapper et al., 2004 (Tapper et al., , 2007 Maskos et al., 2005; Mameli-Engvall et al., 2006; Pons et al., 2008; Exley et al., 2011) . a4b2 * nAChRs are expressed by most neurons of the midbrain DA system (Azam et al., 2002; Nashmi et al., 2007) . a6b2 * nAChRs are the other major nAChR subtype in the mesolimbic DA system. These receptors are also strongly expressed in some VTA and SNc neurons (Azam et al., 2002; Mackey et al., 2012) , and they are necessary for nicotine self-administration (Pons et al., 2008) . GABAergic neurons in the substantia nigra and VTA do not appear to express a6 subunits (Drenan et al., 2008a) , but DA neurons express multiple a6b2
* subtypes: a4a6b2b3, a4a6b2, a6b2b3, and a6b2
(referred to hereafter as ''a6 * '') (Salminen et al., 2004 (Salminen et al., , 2007 Drenan et al., 2010) . Due to their restricted expression pattern in only a few cell types in brain Shih et al., 2014) , along with their high sensitivity to nicotine and ACh (Salminen et al., 2007) , manipulation of a6 * nAChR activity with drugs may offer a more selective approach to treating disorders involving DA transmission (Quik and McIntosh, 2006) . Unfortunately, very few a6-selective drugs have been developed due to the complexity of a6 * nAChR stoichiometry and the challenges associated with in vitro expression and characterization of the various a6 * subtypes (Drenan et al., 2008b; Drenan and Lester, 2012) .
To address these obstacles, we developed and have studied transgenic mice expressing mutant, hypersensitive a6 nAChR subunits. In these mice (referred to as ''a6L9S''), a Leu to Ser mutation at the ''9 prime'' (9 0 ) position in the second transmembrane domain of the a6 subunit renders a6 ⁄ nAChR populations hypersensitive to ACh and nicotine (Drenan et al., 2008a) . Previously, we used these mice to elucidate several aspects of a6 ⁄ nAChR neurobiology. In behavioral experiments, we demonstrated that increased activity of a6 ⁄ nAChRs leads to locomotor activation. Using slice electrophysiology, we found that a6 ⁄ nAChR activity stimulates action potential firing in VTA DA neurons (Drenan et al., 2008a) . A neurochemical analysis revealed that a6L9S mice exhibit enhanced synthesis and release of DA in the NAc and dorsal striatum (Drenan et al., 2008a (Drenan et al., , 2010 Wang et al., 2013) . We also demonstrated that a4 subunits are required for most of these effects, highlighting the importance of a4a6 ⁄ nAChRs (Drenan et al., 2010) . More recently, we used these mice to show that selective activation of a6 ⁄ nAChRs in DA neurons is sufficient to enhance glutamatergic synaptic plasticity, which is a key molecular change occurring during the nicotine dependence/addiction process (Engle et al., 2013 (Engle et al., , 2015 . Despite these advances, important questions remain to be answered to further validate the a6L9S model for future drug discovery studies on mesolimbic DA system a6 ⁄ nAChRs. Although the VTA to NAc pathway is presumed to be the key brain area that mediates most or all of these effects, we have not directly shown this. In the present study, we used behavioral, systems, and biophysical approaches to determine whether the VTA is required for selective a6
⁄ nAChR activation to support locomotor activity and induction of synaptic plasticity.
EXPERIMENTAL PROCEDURES Animals
Adult a6L9S mice and non-transgenic (nonTG) littermates were used in the current study. All mice were maintained on a standard 12-h light/dark cycle at 22°C with food and water ad libitum. Mice were weaned on postnatal day 21 and subsequently group-housed with same-sex littermates. Genotype analysis by polymerase chain reaction (PCR) from tail biopsies was completed as previously described (Drenan et al., 2010) . Care of all animals was carried out in agreement with the National Institutes of Health Office of Laboratory Animal Welfare as well as a protocol approved by the Institutional Animal Care and Use Committee at Purdue University. a6L9S mice were generated as previously published (Drenan et al., 2008a) . Briefly, a Leu9 0 to Ser mutation was introduced into a bacterial artificial chromosome (BAC) at the a6 nAChR subunit gene, Chrna6.
Mutant BAC DNA was then injected into FVB/N embryos and the embryos were implanted into pseudopregnant Swiss-Webster surrogates. The insertion site in the mouse genome is unknown. Founder animals were identified and back-crossed to C57BL/6 mice for 12 or more generations. As a result, 90-95% of the genome of the a6L9S strain is expected to be C57BL/6 although FVB/N allelic DNA close to the insertion site is likely to remain. The L9S mutation leaves a6 ⁄ nAChRs 10-to 100-fold more sensitive to ligands such as nicotine and ACh compared to nona6 ⁄ nAChRs, depending upon the assay (Drenan et al., 2008a (Drenan et al., , 2010 Cohen et al., 2012) .
Previous studies have confirmed that a6 ⁄ nAChRs are not overexpressed, nor expressed in ectopic brain regions in a6L9S mice (Drenan et al., 2008a (Drenan et al., , 2010 .
Drugs and chemicals
(À)Nicotine hydrogen tartrate salt was from Glentham Life Sciences (Wiltshire, United Kingdom). All nicotine doses are reported as freebase. a-conotoxin MII (aCtxMII) was synthesized as described in previously published reports (Azam et al., 2010) . ABT-089 powder was provided by Abbvie (North Chicago, IL, USA). Varenicline, SCH23390, and all other chemicals without a specified supplier were from Sigma (St. Louis, MO, USA).
Locomotor activity
Horizontal locomotor activity in a6L9S mice and nonTG littermates was measured using a Panasonic WV-CP294 camera and converted into distance traveled using TopScan LITE software (CleverSys; Reston, VA, USA). Prior to behavioral testing, all mice were handled, scruffed, and given a saline injection (i.p.) once per day for a minimum of three days. Groups of six to eight mice were placed in a fresh home cage and baseline locomotor activity was recorded in one min intervals for 8 min. Mice were removed from the cage and injected with either a test compound (nicotine, varenicline, etc.) or saline and returned to the cage within 20 s. Locomotor activity was then recorded in one min intervals for >30 min following the injection. For doseresponse studies, mice were administered saline then each successive dose of test compound at 3-4-day intervals.
Bilateral cannulation of VTA and NAc a6L9S mice and nonTG littermates were anesthetized with a ketamine/xylazine cocktail (100 mg/kg ketamine, 10 mg/kg xylazine, injected i.p.). The surgical area was shaved and cleansed via three applications of alternating iodide ointment and 70% ethanol. Mice were then placed into a stereotaxic frame (Kopf; Tujunga, CA, USA) and a small incision was made to expose the skull. The skull was leveled in the coronal and sagittal planes using the coordinates for the bregma and lambda as landmarks. Bilateral holes were drilled in the skull according to adjusted coordinates from the third edition of the Franklin and Paxinos mouse brain atlas (for VTA: M/L: ±0.5 mm from bregma, A/P: À3.2 mm from bregma; for NAc: M/L: ±0.5 mm from bregma, A/P: +1.62 mm from bregma). The A/P coordinate was adjusted for each animal to accommodate individual variations in size; the distance between the bregma and lambda was measured for each mouse and divided by the published distance in this species (4.21 mm), and this ratio was then multiplied by the proper A/P coordinate from the atlas to determine the proper A/P coordinates for each animal. Guide cannulae 3.0 mm in length (Plastics One; Roanoke, VA, USA) along with a dummy cannula (also 3.0 mm in length; Plastics One) were slowly lowered into position and secured using Geristore cement (Den-Mat; Lompoc, CA, USA). Animals remained in the stereotaxic apparatus until the cement fully dried. Once removed from the stereotaxic apparatus, a dust cap was screwed onto the dorsal portion of the guide cannula to keep the dummy cannula in place and to prevent contamination of the guide cannula. Following surgery, mice were given ketoprofen (5 mg/kg, s.c.) and allowed to recover on a heating pad under close observation until ambulatory. Mice were single-housed following cannulation surgery and were allowed to recover for at least 5 days prior to the start of behavioral testing.
Intracranial infusions and locomotor activity a6L9S mice or nonTG littermates received intra-VTA infusions of nicotine (1.7 nmol) or vehicle (sterile saline) approximately 10 min prior to the initiation of each locomotor activity session. To determine the role of a6 ⁄ nAChRs in nicotine-mediated locomotion, some a6L9S mice received intra-VTA co-infusions of nicotine (1.7 nmol) and the a6 ⁄ nAChR antagonist aCtxMII (10 pmol) before the locomotor monitoring session. Infusions were carried out using a dual syringe pump connected to internal cannulae (extending 1.5 mm beyond guide cannulae; Plastics One) via two identical Hamilton syringes and PE50 tubing (Plastics One). Mice were anesthetized using isoflurane (5% for initiation of anesthesia; 1.8% for maintenance). While maintained on isoflurane anesthesia, the dust cap and dummy cannula were removed and the internal cannula was fully inserted into the guide cannula. Drugs were infused at a rate of 0.1 lL/min for 5 min for a total volume of 0.5 lL. The internal cannula was left in place for an additional 5 min to prevent backflow into the guide cannula. Following the infusion, the internal cannula was removed and the dummy cannula and dust cap were replaced. The animal was immediately removed from the isoflurane and allowed to recover in the home cage for 10 min prior to each locomotor activity session. Following recovery from the isoflurane anesthesia, mice were injected with 0.02 mg/kg nicotine (i.p.) or saline, immediately placed into a fresh home cage and locomotor activity was then measured as described above for 30 min. A separate group of a6L9S mice received intra-NAc infusions of either SCH23390 (150 ng) or vehicle (sterile saline) before i.p. saline or nicotine using the procedures detailed above prior to locomotor testing for 30 min. Following the last locomotor activity session, mice were perfused and brains were retained for histological analysis/confirmation of cannula placement.
Nicotine injections for electrophysiology
A set of experiments involved nicotine exposure in a novel environment prior to brain slice preparation for electrophysiology studies. Prior to receiving nicotine injections mice were habituated to being handled. For three consecutive days, at the same time each day, mice were picked up and held but not scruffed. On the fourth day, mice were scruffed and given a mock injection. On the fifth day (the day before the i.p. nicotine injection) mice were scruffed and received an i.p. saline injection. One the day of the experiment mice were given an i.p. nicotine (0.03 or 0.17 mg/kg) or vehicle (saline) injection and placed into a novel environment. A subset of mice were cannulated and given 7-10 days to recover before beginning the handling procedure. These mice were given an infusion of vehicle (saline) or aCtxMII immediately prior to the nicotine injection.
Brain slice preparation
Sixty minutes after the nicotine injection, mice were anesthetized with an injection of sodium pentobarbital (100 mg/kg, i.p.) prior to cardiac perfusion. Brain slices were prepared as previously described . Mice were perfused with oxygenated (95% O 2 /5% CO 2 ) 4°C N-methyl-D-glucamine (NMDG)-based recovery solution containing (in mM): 93 NMDG, 2.5 KCl, 1.2 NaH 2 PO 4 , 30 NaHCO 3 , 20 HEPES, 25 glucose, 5 Na + ascorbate, 2 thiourea, 3 Na + pyruvate, 10MgSO 4 Á7H 2 O, and 0.5 CaCl 2 Á2H 2 O. The osmolarity was adjusted to 300-310 mOsm with sucrose and the pH to 7.3-7.4 with 10 N HCl. Brains were dissected and put in oxygenated 4°C recovery solution for 1 min before cutting 200-lm coronal brain slices through the VTA on a vibrating microslicer. Slices were placed in oxygenated 33°C recovery solution for 12 min and then kept in room temperature holding solution for an hour or more until used for electrophysiology. Holding solution contained (in mM): 92 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 30 NaHCO 3 , 20 HEPES, 25 glucose, 5 Na + ascorbate, 2 thiourea, 3 Na + pyruvate, 2 MgSO 4 Á7H 2 O, and 2 CaCl 2 Á2H 2 O. The osmolality and pH were adjusted to 300-310 mOsm and 7.2-7.4.
Patch-clamp electrophysiology
Patch pipettes were prepared on a P-97 programmable micropipette puller (Sutter Instruments; Novato, CA, USA) from borosilicate glass capillary tubes. The tip resistance was 4.5 to 8.0 MO when filled with an internal solution containing (in mM): 117 CsCH 3 SO 3 , 20 HEPES, 0.4 EGTA, 2.8 NaCl, 5 TEA-Cl, 2.5 MgATP, 0.1 spermine, and 0.25 MgGTP. The osmolarity of the internal solution was adjusted to 290 mOsm with sucrose and the pH was adjusted to 7.25 with Tris base. A VTA-containing brain slice was placed in a recording chamber and superfused at a rate of 1.5-2.0 mL/min with oxygenated 32°C recording solution containing (in mM): 124 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 24 NaHCO 3 , 12.5 glucose, 2 MgSO 4 Á7H 2 O, and 2 CaCl 2 Á2H 2 O. The osmolality and pH were to 300-310 mOsm and 7.2-7.4. Picrotoxin (75 mM) and tetrodotoxin (0.5 lM) were also included in the recording solution to isolate the effect of a-amino-3-hydroxy-5-methyl-isoxazolepropionic acid (AMPA) to the recorded neuron. A Nikon FN-1 upright microscope using infrared or visible differential interference contrast optics was used to visualize neurons. VTA neurons were identified as previously described (Engle et al., 2013) and found at coordinates of approximately À3.5 mm from the bregma, 4.0-4.5 mm ventral to the surface, and 0.5-1.0 mm from the midline. Whole-cell recordings were acquired using the following instruments/software from Molecular Devices Corp. (Sunnyvale, CA, USA): an Axopatch 200B amplifier, a 16-bit Digidata 1440 A/D converter, and pCLAMP 10.3 software.
Cells were held at À60 mV and AMPA receptor (AMPAR) function was analyzed as previously described (Engle et al., , 2013 (Engle et al., , 2015 . A micropipette filled with AMPA (100 lM) was loaded onto a singledimension piezoelectric translator attached to a micromanipulator. pClamp 10 was used to run a protocol that triggered a Picospritzer III to puff-apply AMPA to the recorded neuron with a 250 ms, 12-psi pressure ejection.
The protocol triggered the pipette to move 20-40 lm away from the recorded neuron, trigger the pressure ejection, and then retract the pipette. Movement of the neuron, stability of the seal, and the rise time of the response were all assessed to determine whether the response was optimal. These metrics were previously described (Engle et al., 2013) .
Statistics
Statistical tests were done using GraphPad Prism 6 software. To evaluate statistical significance, data sets were analyzed for normality with a D'Agostino & Pearson omnibus normality test. For all experiments conducted, some experimental groups exhibited parametric distribution while others did not. Therefore, non-parametric distribution was assumed for all data sets, and Mann-Whitney U-tests were performed. p values for statistically significant results are presented in the figure legends.
RESULTS
VTA DA and GABA neurons express moderate to high levels of nAChRs. VTA DA neurons produce a4a6 ⁄ ,
a6(non-a4)
⁄ , and a4(non-a6)
⁄ nAChRs (Salminen et al., 2004 (Salminen et al., , 2007 . In contrast, VTA GABA neurons appear to only express a4(non-a6) ⁄ nAChRs (Drenan et al., 2008a; Powers et al., 2013) . This differential nAChR expression pattern (Fig. 1A) suggests that drugs targeting a4a6
⁄ and/or a6(non-a4)
⁄ nAChRs may offer a unique way to manipulate the mesolimbic DA system in various human disorders. To isolate the action of a6 ⁄ nAChRs in DA neurons, we studied ''a6L9S'' mice. These mice express mutant, hypersensitive a6 ⁄ nAChRs in midbrain DA neurons. This allows low concentrations of nicotine, ACh, or other a6 ⁄ nAChR agonists to be used as highly selective ligands for a6 ⁄ nAChRs (Fig. 1B) .
Locomotor activity in a6L9S mice
Previously, we used a rudimentary beam-break locomotor activity apparatus to study locomotion in a6L9S mice. We reported that a6L9S mice exhibit profound psychomotor activation when low doses of nicotine are administered systemically (Drenan et al., 2008a (Drenan et al., , 2010 Grady et al., 2010; Cohen et al., 2012) . Because nonTG littermate mice do not respond to these low nicotine doses with any change in locomotor activity, we suggested that these behavioral responses were due specifically to a6 ⁄ nAChR activation in midbrain DA neurons. In this study, we have expanded upon those prior/initial studies. To study locomotor activity in a6L9S mice, we employed video tracking software designed to monitor/measure horizontal distance traveled. This system utilizes an overhead video camera that records mouse horizontal movement, allowing the software to create a spatial map of mouse ambulatory activity ( Fig. 2A) . To confirm our previous results, we measured nicotine-stimulated locomotor activity using this system. Mice were placed in a new home cage and allowed to ambulate for 8 min. Then, mice were quickly removed, injected, and returned to the monitoring cage within 20 sec. Locomotor activity was measured for an additional 30 min. As expected, nicotine (i.p.) produced a dose-dependent increase in locomotor activity in a6L9S mice (Fig. 2B) . Nicotine-elicited locomotor activation was robust but brief, often declining to baseline within 30 min or less. Distance-traveled during min 9-15 was significantly increased by 0.02 mg/kg and 0.05 mg/kg nicotine in a6L9S mice compared to nonTG mice (Fig. 2C) .
Next, we conducted several experiments to test the hypothesis that nicotine-elicited locomotor activation in a6L9S mice is mediated by nAChRs in the ventral midbrain. Groups of mice were implanted with bilateral guide cannulae above the VTA. On the day of the experiment, mice were anesthetized with isoflurane. The first goal was to test the ability of intra-VTA aCtxMII to block locomotor activation elicited by systemic nicotine in a6L9S mice. The specificity of aCtxMII is 5.6-fold for a6 ⁄ nAChRs vs. a3
⁄ , and has low antagonist activity at other nAChR subtypes (Cartier et al., 1996; McIntosh et al., 2004) . a3 ⁄ nAChR subunits are expressed at low levels in VTA DA neurons (Champtiaux et al., 2002; Shih et al., 2014) . Thus, in the DA system, and in conjunction with the sensitizing a6L9S manipulation, aCtxMII is sufficient to block the activity of a6 ⁄ nAChRs in the a6L9S model (Drenan et al., 2008a) . Using an internal cannula, we infused aCtxMII (10 pmol) or vehicle into the VTA. At t = 0 min after mice recovered from isoflurane anesthesia and were ambulatory, 0.02 mg/kg nicotine (i.p.) was administered and distance traveled was measured.
Vehicle-infused a6L9S mice responded normally to systemic nicotine, but locomotor activation was blocked in mice infused with aCtxMII (Fig. 3A) . Control saline injections after the same intra-VTA infusion regimen demonstrated the specificity of 0.02 mg/kg nicotine in a6L9S mice (Fig. 3B) . Quantification of distance traveled during the 30-minute experiment demonstrated a significant difference in nicotine-injected (but not saline-injected) mice infused with vehicle and aCtxMII (Fig. 3C ). Cannula placement and injection sites in VTA were verified post-hoc (Fig. 3D ).
To further study the mechanism by which systemic nicotine activates locomotion in a6L9S mice, a6L9S
mice were cannulated to allow delivery of drugs into the nucleus accumbens shell (NAcs). NAcs is a key site of action for a6
⁄ nAChRs in the response to nicotine (Brunzell et al., 2009) . We tested the hypothesis that DA signaling is required for nicotine-elicited locomotor activity in a6L9S mice by infusing mice with the dopamine D1 receptor antagonist SCH23390 (150 ng) prior to a systemic nicotine (0.02 mg/kg, i.p.) challenge. Consistent with a role for dopamine D1 receptor-mediated signaling in a6L9S locomotor activation, SCH23390 infusion into NAcs substantially reduced locomotor activation following systemic nicotine injection (Fig. 4A) . Systemic saline control injections revealed a small but significant effect of SCH23390 alone on locomotor activity (Fig. 4B, C) . Quantification of distance traveled during the 30-minute experiment demonstrated a significant difference in NICinjected mice infused with vehicle vs. SCH23390 (Fig. 4C) . Cannula placement and injection sites in NAcs were verified post-hoc (Fig. 4D ).
Next, we tested the ability of intra-VTA nicotine to recapitulate the effect of systemic nicotine in a6L9S mice. We infused vehicle or nicotine (1.7 nmol) into the VTA. Immediately after isoflurane was removed and mice resumed ambulatory activity, we measured locomotor activity for 30 min. Whereas nonTG mice did not respond appreciably to 1.7 nmol nicotine relative to vehicle (Fig. 5A, E) , a6L9S mice responded with increased locomotor activity when 1.7 nmol nicotine was infused into the VTA (Fig. 5C, E) . Infusion sites were confirmed with histological analysis after the experiment (nonTG: Fig. 5B ; a6L9S: Fig. 5D ). To test the hypothesis that a6
⁄ nAChRs mediate the effect of nicotine in this experiment, a6L9S mice were co-infused with 1.7 nmol nicotine and aCtxMII, an antagonist of a6 ⁄ nAChRs. In contrast to nicotine, co-infusion of nicotine with aCtxMII did not result in locomotor activation in a6L9S mice (Fig. 5C, E) . Together, these results indicate that activation of a6 ⁄ nAChRs in VTA neurons is sufficient to stimulate locomotor activity in mice.
Having confirmed that locomotor activation in a6L9S mice is mediated by a6 ⁄ nAChRs in VTA, we tested the ability of several nicotinic ligands to support a similar behavioral response. Varenicline (Fig. 6A) , an FDAapproved drug for smoking cessation, is a high-affinity partial agonist at a4b2 nAChRs (Coe et al., 2005; Rollema et al., 2007) . More recently, it has also been shown to exhibit similar partial agonism at a6 ⁄ nAChRs in the midbrain DA system (Grady et al., 2010; Bordia et al., 2012) . To further study a6 ⁄ nAChRs using a6L9S
locomotor activation, we tested the ability of varenicline to stimulate locomotor activity in a6L9S mice. As with nicotine, mice injected (i.p.) with low doses of varenicline exhibited a dose-dependent increase in locomotor activity compared to nonTG littermate control mice (Fig. 6D) . Using distance-traveled during min 9-39, varenicline produced a significant increase in locomotor activity at 0.01 mg/kg and 0.03 mg/kg (Fig. 6F ). Next, we tested ABT-089 for its ability to stimulate locomotor activity in a6L9S mice. ABT-089 ( Fig. 6B; also known as pozanicline) is an investigational drug with partial agonist properties at a4b2 and a6
⁄ . In particular, ABT-089 has been reported to possess differential pharmacology at distinct aCtxMII-sensitive nAChRs; it is a partial agonist at a high-affinity a6 ⁄ subtype and a full agonist at a low-affinity a6 ⁄ subtype (Marks et al., 2009) . We speculated that if ABT-089 supported locomotor activity at low doses, this could help confirm its activity at a high-affinity a6 ⁄ subtype. ABT-089 was administered i.p. to a6L9S and nonTG mice and distance traveled was measured. Unlike varenicline, which stimulated locomotor activity at doses such as locomotor activity in a6L9S (n = 19) and nonTG (n = 5) mice. Total distance traveled between and including minutes 9 to 15 from the experiment described in B was summed for each mouse and averaged across all mice in each group. Mean distance traveled from minute 9 to 15 is plotted for each nicotine dose and each strain (a6L9S and nonTG). Mann-Whitney U-test: Doses of 1.0 mg/kg and 3.0 mg/kg ABT-089 were required to elicit appreciable locomotor activation in a6L9S mice (Fig. 6E, G) . These results, combined with experiments employing varenicline, confirm that partial agonists at a6 ⁄ nAChRs are capable of strongly stimulating locomotor activity in the a6L9S system.
Synaptic plasticity in VTA DA neurons
Nicotine exposure is known to alter synaptic plasticity at VTA DA neurons (Saal et al., 2003; Gao et al., 2010; Jin et al., 2011; Mao et al., 2011) . Previously, we demonstrated that incubating brain slices from naı¨ve animals with low concentrations of nicotine causes a6 ⁄ nAChR activation and enhanced AMPAR function in VTA DA neurons (Engle et al., 2013 (Engle et al., , 2015 . In this study, we sought to determine whether in vivo activation of a6 ⁄ nAChRs is sufficient to support changes in VTA DA neuron excitability. We tested the ability of in vivo nicotine administration to act selectively through a6 ⁄ nAChRs to enhance AMPAR function on the surface of these cells. a6L9S
and nonTG control littermate mice were injected (i.p.) with nicotine or vehicle. After 60 min, mice were sacrificed and brain slices were prepared (Fig. 7A) . AMPAR function was measured using local application of AMPA to the recorded cell using a puff-pipette as previously described and validated (Engle et al., , 2013 (Engle et al., , 2015 . Based on the dose-range found to be sufficient to stimulate locomotor activity in a6L9S mice (0.02 to 0.05 mg/kg; Fig. 2 ), a6L9S and nonTG mice were injected with 0.03 mg/kg nicotine or vehicle. This dose was sufficient to enhance AMPA-evoked currents on the surface of VTA DA neurons in a6L9S mice, but was below threshold in nonTG mice (Fig. 7B, C) . A relatively high dose of nicotine (0.17 mg/kg) was needed to increase the amplitude of AMPA-evoked currents on the surface of VTA DA neurons from nonTG mice (Fig. 7B, C) . Thus, a single systemic exposure to nicotine can act through a6 ⁄ nAChRs to enhance glutamatergic transmission in VTA DA neurons. Fig. 3 . VTA aCtxMII-sensitive nAChRs mediate locomotor activation in a6L9S mice. (A) Locomotor activity in a6L9S mice infused into the VTA with vehicle (n = 7) or aCtxMII (10 pmol; n = 8) prior to systemic nicotine (0.02 mg/kg) injection. a6L9S mice were infused as indicated, followed by injection (i.p.) with nicotine prior to locomotor activity monitoring for 30 min. (B) Locomotor activity in a6L9S mice infused into the VTA with vehicle (n = 7) or aCtxMII (10 pmol; n = 7) prior to systemic saline injection. a6L9S mice were infused as indicated, followed by injection (i.p.) with saline prior to locomotor activity monitoring for 30 min. (C) Quantification of distance traveled for a6L9S mice injected with saline or nicotine following infusion of either vehicle or aCtxMII. Mann-Whitney U-test: Last, we tested the hypothesis that systemic, lowdose nicotine administration in a6L9S mice acts through ventral midbrain a6 ⁄ nAChRs to enhance AMPA-evoked currents. Prior to nicotine (0.03 mg/kg; i.p.) challenge, the VTA of a6L9S mice was infused with aCtxMII (10 pmol) or vehicle (Fig. 8A ). Brain slices were prepared and AMPA-evoked currents were measured as in Fig. 7 . The nicotine-elicited increase in AMPAR function was abolished when aCtxMII was infused into the VTA (Fig. 8B, C) . aCtxMII infusion paired with a vehicle injection did not show any change over baseline. Injection sites in the VTA were verified post-hoc (Fig. 8D) . These data, along with Fig. 7 , demonstrate that in vivo activation of VTA a6 ⁄ nAChRs is sufficient to drive synaptic plasticity changes in VTA DA neurons that are known to be important for locomotor sensitization and reward behavior.
DISCUSSION

a6
⁄ nAChRs in VTA mediate locomotor activation
In this study, we began by re-assessing previous studies showing that low doses of nicotine stimulate locomotor activity in a6L9S mice. Whereas these previous studies utilized a low-resolution locomotor activity system, the current study employed video tracking software to monitor distance traveled and velocity. The current data are very consistent with results published in 2008 (Drenan et al., 2008a) . The magnitude and duration of nicotine-elicited locomotor responses are comparable between the two studies (Drenan et al., 2008a) . Transgenes in transgenic animals are known to undergo silencing, resulting in reduced transgene expression (Mehtali et al., 1990) . a6L9S mice harbor 10 or more copies of the a6L9S transgene (Drenan et al., 2008a) , but the present results suggest that there has been no appreciable functional loss of a6L9S transgene expression compared to mice in the original study.
Mouse behaviors, including behaviors resulting from transgene expression, are also known to be sensitive to genetic background. The a6L9S mice were originally generated using FVB/N embryos, and each generation has been back-crossed to C57BL/6. Whereas mice used to generate behavioral data in the original study were back-crossed less than 10 times to C57BL/6, mice in the present study have been back-crossed to ⁄ nAChRs in VTA. (A) Low-dose nicotine infusion into VTA of nonTG mice does not stimulate locomotor activity. Vehicle (VEH; n = 6) or 1.7 nmol of nicotine (NIC 1.7 nmol; n = 6) was infused into the VTA of isoflurane-anesthetized nonTG mice. Following infusion, mice were immediately removed from isoflurane and locomotor activity was measured for 30 min. (B) Cannula placement in VTA for infusions of VEH/NIC in VTA of nonTG mice. Approximate site of nicotine delivery is marked with a purple dot. (C) Nicotine infusion into VTA of a6L9S mice stimulates locomotor activity, and co-infusion of nicotine with aCtxMII blocks locomotor activation. Vehicle (VEH; n = 8), 1.7 nmol of nicotine (NIC 1.7 nmol; n = 6), or 1.7 nmol of nicotine plus 10 pmol of aCtxMII (NIC 1.7 nmol + MII 10 pmol; n = 8) were infused into the VTA of isoflurane-anesthetized mice. Following infusion, mice were immediately removed form isoflurane and locomotor activity was C57BL/6 20 times or more and therefore contain more C57BL/6 allelic DNA. Our data showing that locomotor activation in a6L9S mice is comparable to the original study imply that the locomotor phenotype in a6L9S mice appears quite stable on the C57BL/6 background.
Although a6 nAChR subunit expression is sparse in the brain compared to a4 subunits, there are still several brain areas displaying measurable a6 subunit expression. a6 subunits are expressed in noradrenergic neurons of the locus coeruleus (Drenan et al., 2008a) , which send projections to brain areas such as the cerebral cortex and hippocampus (Azam and McIntosh, 2006). a6 subunits are also expressed by a subset of retinal ganglion cells, a sparse population of neurons in the dorsal lateral geniculate nucleus of the thalamus, and are widely expressed in several layers of superior colliculus . a6 subunits are also expressed in medial habenula to interpeduncular nucleus pathway (Henderson et al., 2014; Shih et al., 2014) , and have recently been shown to play an important role in nociception via their expression in spinal cord (Wieskopf et al., 2015) . Although the DA system is the most logical candidate to mediate nicotineelicited locomotor activation, several of these areas also have a plausible link to the locomotor system.
Additionally, many studies probing the role of a6 ⁄ nAChRs rely heavily on aCtxMII, which has modest affinity ) and nonTG (n = 8) mice. a6L9S or nonTG littermate mice were placed in a fresh home cage and locomotor activity was recorded. After 8 min to establish baseline locomotor activity, mice were injected with vehicle (saline) and immediately returned to the cage for an additional 30 min of monitoring. (D) Locomotor activation in a6L9S mice by varenicline using procedures described in (C). Locomotor activation in a6L9S or nonTG littermate mice was measured following injection with the indicated dose of varenicline (0.03, 0.01, or 0.003 mg/kg; i.p.). (E) Locomotor activation in a6L9S mice by ABT-089 using procedures described in (C). Locomotor activation in a6L9S or nonTG littermate mice was measured following injection with the indicated dose of ABT-089 (0.3, 1.0, or 3.0 mg/kg; i.p.). (F) Quantification of vareniclineelicited locomotor activity in a6L9S (n = 16) and nonTG (n = 8) mice. Total distance traveled between and including minutes 9 to 39 from the experiment described in (D) was summed for each mouse and averaged across all mice in each group. Mean distance traveled from minute 9 to 39 is plotted for each varenicline dose and each strain (a6L9S and nonTG). Mann-Whitney U-test: ⁄⁄⁄⁄ p < 0.0001. (G) Quantification of ABT-089-elicited locomotor activity in a6L9S (n = 16) and nonTG (n = 8) mice. Total distance traveled between and including minutes 9 to 39 from the experiment described in (E) was summed for each mouse and averaged across all mice in each group. Mean distance traveled from minute 9 to 39 is plotted for each ABT-089 dose and each strain (a6L9S and nonTG). Mann-Whitney U-test:
for a3 ⁄ nAChRs (Cartier et al., 1996) . Expression of a3 ⁄ nAChRs in midbrain DA neurons has not been completely ruled out (Azam et al., 2002) , and could theoretically play a role in some nicotine-mediated responses. Thus, we employed intracranial manipulations in a6L9S mice to probe the role of the VTA and a6
⁄ nAChRs in mediating the locomotor phenotype we observed.
Nicotine delivered into the VTA of a6L9S mice is sufficient to recapitulate the effect of systemic nicotine in the locomotor activity assay, and co-infusion of nicotine with aCtxMII blocks the action of nicotine alone (Fig. 5) . Thus, no other brain areas or pathways that express a6 subunits besides the VTA are required to produce locomotor activity in a6L9S mice. Our results build upon previous results in the rat brain showing that intracerebroventricular infusion of a6 nAChR antisense oligos blocks nicotine-stimulated locomotor activation (le Novere et al., 1999) . Our data are also complementary to data presented in another study; Gotti and colleagues demonstrated that aCtxMII-sensitive nAChRs in VTA are required for nicotine-elicited locomotor activation, DA release in NAc, and nicotine self-administration in rats (Gotti et al., 2010) . Our data are also consistent with previous results showing that re-expression of a6 subunits in the VTA of a6 knockout mice is sufficient to restore acute nicotine self-administration (Pons et al., 2008) . It should be noted, however, that the generalizability of these results to nicotine-induced modulation of locomotor activity in wild-type mice is limited. C57BL/6 wild-type mice exhibit locomotor suppression at moderate ($0.5 mg/kg) nicotine doses (Drenan et al., 2008a) . The mechanism behind this suppression is not clear, but could involve a dominant role for GABA release in the mesolimbic DA system via a4b2 nAChRs. By ''bypassing'' a4b2 activation on GABA neurons by the use of hypersensitive a6 ⁄ nAChRs expressed only on DA neurons, locomotor results in a6L9S mice may support this conclusion regarding GABA release and nicotine-mediated locomotor suppression. ⁄ nAChR subtypes that may mediate locomotor activation in a6L9S mice, we used two additional agonists in addition to nicotine. Varenicline, in addition to its known partial agonist activity at a4b2 nAChRs (Coe et al., 2005; Rollema et al., 2007) , has recently been shown to posses high affinity for and partial agonist activity at a6 ⁄ nAChRs in the DA system. Using agonist-evoked DA release from mouse striatal synaptosomes, Grady and colleagues measured varenicline-induced release at aCtxMIIresistant (a4b2 and a4a5b2 nAChRs) and aCtxMIIsensitive (a4a6b2b3, a4a6b2, a6b2b3, and a6b2 nAChRs) receptors (Grady et al., 2010) . Varenicline is a high-affinity partial agonist at both subtypes (26% of nicotine and 50 nM EC 50 at aCtxMII-resistant nAChRs; 39% of nicotine and 75 nM EC 50 at aCtxMII-sensitive nAChRs) (Grady et al., 2010) . Similar studies in rat and monkey synaptosomes indicate varenicline may possess slight selectivity for aCtxMII-sensitive vs. -resistant nAChRs (Bordia et al., 2012) . Varenicline stimulated locomotor activity in a6L9S mice at doses that did not affect locomotion in nonTG mice (Fig. 6 ), but with kinetics that differed from those of nicotine. The latency to reach peak distance traveled was greater for varenicline compared to nicotine. For example, 0.05 mg/kg nicotine caused mice to reach peak distance traveled within $2 min whereas mice injected with 0.03 mg/kg varenicline took $8 min to reach peak distance traveled. Peak distance traveled, once achieved by a6L9S mice, was similar for nicotine and varenicline. However, the duration of agoniststimulated locomotor activity differed for the two drugs. Nicotine-induced locomotor activity fell back to baseline levels within $30 min for all doses of nicotine tested, whereas varenicline-induced locomotor activity remained elevated at $30 min after injection. These kinetic differences could be due to full versus partial agonism for the two drugs, differences in metabolism and bioavailability, or some combination thereof. In mice, nicotine is metabolized within 7-10 min (Matta et al., 2007) , whereas varenicline levels persist for much longer (Obach et al., 2006) .
ABT-089, also known as pozanicline, was developed as a nAChR subtype-selective partial agonist for the treatment of neurological disorders . Indeed, ABT-089 has cognition-enhancing properties Lin et al., 1997) , improves attention (Prendergast et al., 1998) , reduces nicotine intake (Lee et al., 2014) , reduces L-Dopa-induced dyskinesias in Parkinson's disease models (Zhang et al., 2014) , and has shown efficacy in human clinical trials for attention deficit hyperactivity disorder (Wilens et al., 2006) . Although originally characterized as an a4b2-specific ligand, later pharmacology studies demonstrated significant activity at a6 ⁄ nAChRs. Using striatal DA release assays, Marks and colleagues demonstrated that ABT-089 is a highpotency (EC 50 = 0.11 lM) partial agonist (36% of nicotine) at one aCtxMII-sensitive nAChR subtype, and is a low-potency (28 lM) full agonist (98% of nicotine) at another aCtxMII-sensitive subtype (Marks et al., 2009 ). Marks and colleagues speculated that because a4a6 ⁄ nAChRs exhibit high sensitivity to nicotine and ACh (Salminen et al., 2007) , ABT-089 may be acting at this subtype to mediate its actions at low (nanomolar) concentrations (Marks et al., 2009) . To determine what nAChR subtype ABT-089 acts on in vivo, we were interested to determine whether ABT-089 would activate locomotor activity at similar doses as varenicline. Although capable of stimulating locomotor activity specifically in a6L9S mice and not in nonTG littermates, much higher doses of ABT-089 were required relative to varenicline doses. These results suggest that varenicline and ABT-089 may act on different a6 ⁄ nAChR subtypes in vivo. ABT-089 did share similar properties with varenicline with regard to latency to reach peak distance traveled and the duration of locomotor responses (Fig. 6E) . Although the differences in kinetics between nicotine-mediated locomotor activation and activity induced by either of varenicline or ABT-089 are speculated to be due to the partial agonist properties of these ligands, this has not been shown at a6L9S ⁄ nAChRs. Mutations in nAChR transmembrane a-helices are known to alter the pharmacology of ligands, in some cases converting partial agonists to full agonists, or antagonists to agonists (Bertrand et al., 1992) . Kinetic differences in locomotor activation could be fully accounted for by differences in metabolism between nicotine and varenicline/ABT-089.
VTA a6
⁄ nAChRs and synaptic plasticity To connect our in vivo locomotor activity data, which measures a6 ⁄ nAChR activation in VTA, with cellular and molecular events that are relevant to nicotine addiction, we recorded from VTA DA neurons using brain slice patch-clamp electrophysiology. In vivo exposure to nicotine, along with other drugs of abuse such as cocaine and alcohol, results in long-term potentiation (LTP) of excitatory glutamatergic inputs to VTA DA neurons (Ungless et al., 2001; Saal et al., 2003) . Such changes in LTP are typically measured by recording AMPA/NMDA ratios, as enhanced AMPAR function is often the driver of LTP in VTA (Wolf et al., 2004) . These changes in synaptic plasticity underlie important druginduced behavioral changes, including behavioral sensitization, reward memories, and self-administration. With regard to nicotine exposure, it is critical to determine which nAChR subtype(s) mediate this effect. Doing so could lead to novel therapeutic approaches for treating nicotine addiction and/or addiction to other drugs of abuse. Our results in a6L9S mice indicate that systemic administration of a6-selective doses of nicotine (0.03 mg/kg; Fig. 7B, C) is sufficient to enhance AMPAR function on VTA DA neurons. This result was directly ascribed to a6 ⁄ nAChRs, as aCtxMII infusion into VTA blocked the effect of systemic nicotine (Fig. 8B, C) . These data are consistent with our previous results. When naı¨ve brain slices containing VTA were treated with nicotine, AMPAR function (Engle et al., 2013) and AMPA/NMDA ratios (Engle et al., 2015) were enhanced via activation of a6 ⁄ nAChRs. These prior studies also demonstrated, in naı¨ve slices, that a4 subunits and NMDAR activity are also required for a6 ⁄ -mediated increases in AMPAR activity (Engle et al., 2013) . This enhanced AMPAR activity was due to an increase in the potency of agonists at the AMPAR, not because such agonists had increased efficacy (Engle et al., 2013) . Ca 2+ /calmodulin kinase II activity was also required for this effect (unpublished observations), but a7 nAChR activity was not (Engle et al., 2013) . Future studies on in vivo a6 ⁄ nAChR activation signaling in VTA DA neurons could help to determine whether the same signaling mechanisms operating in naı¨ve slice experiments also drive the effects we report here. Taken together, our results isolating a6 ⁄ nAChR activity in VTA using local infusion of aCtxMII reinforce the notion that the VTA is a critical site for the cellular changes induced by nicotine exposure.
Conclusions
In summary, using behavioral and cellular measures of a6 ⁄ nAChR function, we have demonstrated that the VTA is a key site of action for nicotine at a6 ⁄ nAChRs. Our results also show that varenicline is capable of strongly modulating a6 ⁄ nAChR activity, whereas ABT-089 has lower potency at these receptors. Given the ability of varenicline to foster smoking cessation, further research should be done to discriminate its actions at a4b2 versus a6 
